Floatz logo

Vorinostat

Transitional Cell Carcinoma of the Bladder

National Cancer Institute (NCI)Small moleculePhase 2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

38 Active assets in the Transitional Cell Carcinoma of the Bladder cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
Nagoya University
Phase 3BB
Atezolizumab
KaliVir Immunotherapeutics
Phase 3BB
Carboplatin
Jonsson Comprehensive Cancer Center
Phase 2BB
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4)
Fred Hutchinson Cancer Center
Phase 2BB
Pembrolizumab
Fred Hutchinson Cancer Center
Phase 3BB

View all 50 →

Same molecule, other indications

Vorinostat is also rated in:

Non-Small-Cell Lung CarcinomaDormant
BB
Indicative ·
71 / 100
View asset →
Hodgkins lymphomaDormant
BB
Indicative ·
68 / 100
View asset →
Recurrent Non-Hodgkin LymphomaDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →